There might be a new treatment for opioid dependency, as a trial injection treatment was a success.
We can help your practice stay on top of the latest healthcare news, rules, regulations and trends. Subscribe to stay current and up to date on important matters that will impact your practice. (To subscribe to our blog click here).
Opioid addiction has become a nationwide epidemic affecting many in the U.S. Now it appears there may be hope in the form of an injectable treatment called CAM2038.
In 2014 alone, over 47,000 Americans died from overdoses.
The treatment from Braeburn Pharmaceuticals and Camurus is made effective by the drug buprenorphine.
In 2014, approximately 650,000 people in the U.S. received buprenorphine to treat their addiction. Currently, the drug is on the market as tablets that dissolve in the mouth that are to be taken regularly.
The drug could potentially help addicts by easing cravings for opioids and preventing withdrawal symptoms.
The successful trial is important because a long-acting injectible version could provide stable treatment for addicts. The current form of tablets are easy to sell to other addicts and often people run out of them or choose not to take them. A weekly or monthly injection is a desirable option.
During the test, there were no overdoses reported in the individuals that were using the injection.
Braeburn and Camurus plan to work with the FDA and European Medicines Agency to begin the submission process.
The drug is to be submitted for approval by mid-2017.
In our next blog post, we will keep you informed of related issues. To get this important information delivered directly to your mail box, click here to Subscribe.
Do you need help staying current and compliant with the latest laws, rules and regulations? We can help. To contact us about your new government rules and regulations, your practice’s risk assessment, or about your other legal needs: CLICK HERE.
P.S. If you or your patients are interested in consumer healthcare issues, check out myhealthspin.com.